Drug intelligence / Profile preview

ivicentamab

Development stage: Discontinued
Lead developer: Genmab
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Ivicentamab (GEN3009) is a humanized IgG1 bispecific monoclonal antibody that targets two distinct epitopes on the CD37 antigen. It incorporates an E430G hexamerization-enhancing mutation to promote the formation of antibody hexamers at the surface of CD37-expressing tumor cells. This design enhances complement-dependent cytotoxicity (CDC) and also mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). The drug was developed using Genmab’s DuoBody and HexaBody technologies. Its primary indication was for relapsed or refractory B-cell non-Hodgkin lymphoma, including subtypes such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL)[1][2][6].

Other names: ivicentamab

Targets

CD37

Beyond the preview

Go deeper on ivicentamab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ivicentamab.

Explore the full profile